ArticleCancer2018
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase.
Article in Cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Early predictors of MR4.5 attainment and eligibility for TKI discontinuation in CML treated with second-generation TKIs.Blood advances · 2026Trial
- Prognostic factors in chronic myeloid leukemia: at diagnosis and for treatment-free remission.Haematologica · 2026Review
- Development of a blood test-based predictive scoring tool for treatment response in chronic myeloid leukemia.International journal of hematology · 2026Article
- Artificial intelligence-driven label-free detection of chronic myeloid leukemia cells using ghost cytometry.Scientific reports · 2025Article
- BCR::ABL1-induced mitochondrial morphological alterations as a potential clinical biomarker in chronic myeloid leukemia.Cancer science · 2025Article
- Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia: Strategies to Optimize Success and New Directions.Current hematologic malignancy reports · 2024Review
- Prognosis in Chronic Myeloid Leukemia: Baseline Factors, Dynamic Risk Assessment and Novel Insights.Cells · 2023Review
- Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response.NPJ systems biology and applications · 2022Article
- Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia.Leukemia · 2022Review
- Influence of Telomere Length on the Achievement of Deep Molecular Response With Imatinib in Chronic Myeloid Leukemia Patients.HemaSphere · 2021Article
- Treatment-Free Remission in Chronic Myeloid Leukemia: Can We Identify Prognostic Factors?Cancers · 2021Review
- Enabling access to molecular monitoring for chronic myeloid leukemia patients is cost effective in China.PloS one · 2021Article
- A Review on the Therapeutic Role of TKIs in Case of CML in Combination With Epigenetic Drugs.Frontiers in genetics · 2021Review
- Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?Hematology. American Society of Hematology. Education Program · 2020Review
- Handling challenging questions in the management of chronic myeloid leukemia: when is it safe to stop tyrosine kinase inhibitors?Blood advances · 2020Article
- Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia.Current hematologic malignancy reports · 2019Review
- Chronic myeloid leukemia: the concepts of resistance and persistence and the relationship with the BCR-ABL1 transcript type.Leukemia · 2019Review
- Detecting the stable point of therapeutic effect of chronic myeloid leukemia based on dynamic network biomarkers.BMC bioinformatics · 2019Article
- Chronic Myeloproliferative Neoplasms: Some Remaining Challenges.HemaSphere · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundThe achievement of a sustained deep molecular response is a goal of increasing relevance because it opens the possibility of treatment discontinuation. The objective of this analysis was to develop a prediction model for a sustained molecular response with BCR-ABL1 level <0.0032% on the international scale (MR
methodsData for 603 patients with newly diagnosed chronic myeloid leukemia in chronic phase in consecutive prospective clinical trials were analyzed. The best fit average molecular response was defined by robust linear regression models, with which the average molecular levels were defined. The minimum acceptable molecular response was defined by quantile regression for the 95th percentile, with which the worst 5% BCR-ABL1 levels were identified.
resultsIn 603 patients with a median follow-up of 103 months, 2002 BCR-ABL1-level data points within 1 year of tyrosine kinase inhibitors were identified. The regression equation for the best fit average levels for a sustained MR
conclusionsThis model proposes optimal values that predict the highest probability of reaching such a goal. These values can be used to guide therapy when a sustained MR
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.